title: [The Clinical Role of the Neutrophil/Lymphocyte Ratio in Patients with Advanced Gastric Cancer Treated with Protein-Bound Polysaccharide K and Chemotherapy].
abstract: This study aimed to evaluate the efficacy of protein-bound polysaccharide K (PSK)-containing chemotherapy in patients with unresectable advanced or recurrent gastric cancer (AGC). We retrospectively analyzed 190 patients with AGC who received systemic chemotherapy including 69 patients who were treated with a PSK-containing regimen. Using propensity score matching, we obtained 62 matched patients in the S-1 and S-1 plus PSK groups for outcomes analysis. There was a tendency for overall survival to be higher in the S-1 plus PSK group than in the S-1 alone group. In particular, there was a tendency for overall survival in the S-1 plus PSK group to be higher in patients with a neutrophil/lymphocyte ratio (NLR)<2.2 than in patients with a NLR<2.2. There was a tendency for fewer changes in the NLR after the beginning of treatment in the S-1 plus PSK group than in the S-1 alone group. PSK-containing chemotherapy may contribute to improved treatment outcomes of AGC patients. In particular, it may be effective in patients with a high NLR. Further investigations, including a prospective randomized controlled trial, are expected to verify the mechanisms of interaction between cancer cells and the immunoreaction.
authors.affiliation: Dept. of Surgery, Kochi Medical School.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Namikawa
authors.forename: Eri
authors.initials: E
authors.lastname: Munekage
authors.forename: Masaya
authors.initials: M
authors.lastname: Munekage
authors.forename: Mai
authors.initials: M
authors.lastname: Shiga
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Maeda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kitagawa
authors.forename: Ken
authors.initials: K
authors.lastname: Okamoto
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Kumon
authors.forename: Michiya
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Hanazaki
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D007958:Leukocyte Count; D008214:Lymphocytes; D009504:Neutrophils; D010094:Oxonic Acid / Q000008:administration & dosage; D011134:Polysaccharides / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D011134:Polysaccharides; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid